Prevalence, Costs and Consequences of “Manovra AIFA” for ICS-LABA Treatment in Patients with Asthma or COPD: A Real-Practice Analysis

L'impatto della manovra AIFA sui costi di trattamento con ICS-LABA: focus sui pazienti affetti da asma e BPCO

  • Alessandra Bettiol Dipartimento di Scienze del Farmaco, Università degli Studi di Padova, Padova - Italy
  • Jenny Bolcato U.O.C. Politiche del Farmaco e Governo della Spesa Farmaceutica, Azienda ULSS 9 di Treviso, Treviso - Italy
  • Roberta Pirolo U.O.C. Politiche del Farmaco e Governo della Spesa Farmaceutica, Azienda ULSS 9 di Treviso, Treviso - Italy
  • Giulia Franchin U.O.C. Politiche del Farmaco e Governo della Spesa Farmaceutica, Azienda ULSS 9 di Treviso, Treviso - Italy
  • Paola Deambrosis U.O.C. Politiche del Farmaco e Governo della Spesa Farmaceutica, Azienda ULSS 9 di Treviso, Treviso - Italy
  • Pietro Giusti Dipartimento di Scienze del Farmaco, Università degli Studi di Padova, Padova - Italy
  • Alessandro Chinellato U.O.C. Politiche del Farmaco e Governo della Spesa Farmaceutica, Azienda ULSS 9 di Treviso, Treviso - Italy
Keywords: ICS-LABA, “Manovra” AIFA, Price in real practice, Respiratory market

Abstract

Introduction The pharmaceutical respiratory market represents a growing expenditure for the National Healthcare System (NHS), mainly due to the increasing use of corticosteroid + long-acting β2 agonist (ICS-LABA) associations. Following a supplementary budget program (“manovra AIFA”, MA) in 2015, a reduction in drug costing was put in place which resulted in a de facto reduction in price and/or in a pay back provision (2015-2017). This study aimed to evaluate the impact of MA on ICS-LABA and on total direct respiratory costs for ICS-LABA-treated patients. Methods A retrospective study conducted in the Local Health Authority of Treviso identified users of ICS-LABA in 2014. Patients with asthma or COPD were separately analyzed, according to patient exemptions. The expenditure for ICS-LABA and its variation following the MA were assessed; total direct respiratory costs were also calculated. Results ICS-LABA users were 9,017 and 41.18% of them had an exemption for asthma or COPD. Considering dual-indication ICS-LABA medications, the total annual cost was €842,234; after the MA, this expenditure will probably be reduced by 8.2%. Costs were higher in COPD patients compared to patients with asthma (€2,268.97 vs. €535.77 per patient/year), due to more frequent hospitalizations (22.0% vs. 2.9%). For patients with asthma, pharmaceutical treatment costs were the most expensive (78.4% of total costs). Discussion and conclusions A reduction in costs for respiratory medications occurred following the MA, but real savings for the NHS are difficult to estimate, due to the variability in delivery volume and in the consequent pay back quantification.
Published
2016-10-18
How to Cite
BettiolA., BolcatoJ., PiroloR., FranchinG., DeambrosisP., GiustiP., & ChinellatoA. (2016). Prevalence, Costs and Consequences of “Manovra AIFA” for ICS-LABA Treatment in Patients with Asthma or COPD: A Real-Practice Analysis. Global & Regional Health Technology Assessment, 3(3), 115-124. https://doi.org/10.33393/grhta.2016.417
Section
Original Research Article

Most read articles by the same author(s)